Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WM5O
|
|||
| Former ID |
DIB019887
|
|||
| Drug Name |
G1
|
|||
| Synonyms |
CHEMBL569766; 1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]ethanone; 1-(4-(6-Bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)-ethanone; SR-01000506928; AC1NT1SF; GTPL1014; SCHEMBL12700948; cid_5322399; cid_3136849; MolPort-003-004-976; ML051; HMS3650I22; ZINC4172149; BDBM50303803; STK330808; AKOS015969580; HY-107216; CS-0027669; UNM000011063001; UNM000000675701; SR-01000506928-1; SR-01000506928-3; 925419-53-0
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-10: C81-C86; ICD-9: 202] | Phase 1/2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | ||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C21H18BrNO3
|
|||
| Canonical SMILES |
CC(=O)C1=CC2=C(C=C1)NC(C3C2C=CC3)C4=CC5=C(C=C4Br)OCO5
|
|||
| InChI |
1S/C21H18BrNO3/c1-11(24)12-5-6-18-15(7-12)13-3-2-4-14(13)21(23-18)16-8-19-20(9-17(16)22)26-10-25-19/h2-3,5-9,13-14,21,23H,4,10H2,1H3/t13-,14+,21-/m1/s1
|
|||
| InChIKey |
VHSVKVWHYFBIFJ-HKZYLEAXSA-N
|
|||
| CAS Number |
CAS 881639-98-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:156296
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | G-protein coupled estrogen receptor 1 (GPER1) | Target Info | Agonist | [2] |
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04130516) Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801alone and in Combination With Pembrolizumab. U.S. National Institutes of Health. | |||
| REF 2 | Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006 Apr;2(4):207-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.